Ozempic maker Novo Nordisk to boost production through …
1 day ago · Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a takeover of US health products manufacturer Catalent, in a deal worth $11. ...
Novo Nordisk Set to Close Catalent Deal Without FTC Challenge
2 days ago · Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal Trade Commission declined to challenge the deal.
Regulatory conditions on Novo Holdings' $16.5 billion Catalent …
1 day ago · Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, which makes the blockbuster GLP-1 injectable weight-loss drug Wegovy. News Today's news
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, …
2 days ago · Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on ...
Latest news - Novo Nordisk
Nov 5, 2024 · Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events
Novo Nordisk Q3 2024 results - CNBC
Nov 6, 2024 · Novo Nordisk on Wednesday reported a third-quarter beat on sales of its blockbuster weight-loss drug Wegovy and narrowed its 2024 full-year growth guidance. Company shares jumped early on...
Company announcements & press releases - Novo Nordisk
Product-related press releases will only be available upon request after three weeks of publication on our website in order to comply with applicable regulation.
News Details - novonordisk.com
Oct 21, 2024 · Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial Bagsværd, Denmark, 21 October 2024 — Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial.
Novo Nordisk strikes $11bn deal to expand production of weight …
Feb 5, 2024 · Novo Nordisk has agreed to acquire three manufacturing sites for $11bn, as the Danish drugmaker races to expand production of the weight loss drugs whose runaway success has sent the company’s...
Novo Nordisk A/S: The acquisition of Catalent by Novo
2 days ago · Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on ...
- Some results have been removed